PriceTargets.com logo

Structure Therapeutics - GPCR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $85.67
  • Forecasted Upside: 172.13%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$31.48 As of 12/17/2024 01:00 AM ET
▲ +0.48 (1.55%)

This chart shows the closing price for GPCR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Structure Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GPCR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GPCR

Analyst Price Target is $85.67
▲ +172.13% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Structure Therapeutics in the last 3 months. The average price target is $85.67, with a high forecast of $118.00 and a low forecast of $65.00. The average price target represents a 172.13% upside from the last price of $31.48.

This chart shows the closing price for GPCR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Structure Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/4/2024HC WainwrightInitiated CoverageBuy$80.00
9/23/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00 ➝ $65.00
9/23/2024Morgan StanleyInitiated CoverageOverweight$118.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00 ➝ $65.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00 ➝ $65.00
8/15/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00 ➝ $65.00
8/9/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$91.00 ➝ $86.00
7/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00 ➝ $65.00
6/17/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00 ➝ $65.00
6/7/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$83.00 ➝ $100.00
6/3/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00 ➝ $65.00
5/21/2024JPMorgan Chase & Co.Initiated CoverageOverweight$65.00
5/10/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$91.00
5/3/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00
4/18/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00
4/9/2024Cantor FitzgeraldInitiated CoverageOverweight$65.00
2/27/2024Lifesci CapitalReiterated RatingOutperform
11/15/2023JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$90.00 ➝ $91.00
10/26/2023Piper SandlerBoost TargetOverweight ➝ Overweight$58.00 ➝ $93.00
10/19/2023JMP SecuritiesInitiated CoverageOutperform$90.00
10/3/2023BMO Capital MarketsBoost TargetOutperform ➝ Outperform$40.00 ➝ $83.00
10/2/2023GuggenheimBoost Target$50.00 ➝ $92.00
9/29/2023Leerink PartnersBoost Target$46.00 ➝ $97.00
9/29/2023Jefferies Financial GroupBoost TargetBuy ➝ Buy$50.00 ➝ $79.00
7/27/2023Piper SandlerInitiated CoverageOverweight$58.00
5/25/2023Jefferies Financial GroupInitiated CoverageBuy$34.00 ➝ $41.00
2/28/2023Leerink PartnersReiterated RatingOutperform
2/28/2023GuggenheimInitiated CoverageBuy$50.00
2/28/2023SVB SecuritiesInitiated CoverageOutperform$33.00
2/28/2023Jefferies Financial GroupInitiated CoverageBuy$34.00
2/28/2023BMO Capital MarketsInitiated CoverageOutperform$40.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

1.25 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 18 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 6 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
7/21/2024
  • 10 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 9 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 15 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
10/19/2024
  • 3 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/18/2024
  • 25 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 25 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Structure Therapeutics logo
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $31.48
Low: $29.99
High: $31.68

50 Day Range

MA: $35.95
Low: $30.10
High: $41.15

52 Week Range

Now: $31.48
Low: $26.61
High: $62.74

Volume

481,927 shs

Average Volume

784,213 shs

Market Capitalization

$1.80 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Structure Therapeutics?

The following Wall Street analysts have issued reports on Structure Therapeutics in the last year: BMO Capital Markets, Cantor Fitzgerald, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Lifesci Capital, and Morgan Stanley.
View the latest analyst ratings for GPCR.

What is the current price target for Structure Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Structure Therapeutics in the last year. Their average twelve-month price target is $85.67, suggesting a possible upside of 172.1%. Morgan Stanley has the highest price target set, predicting GPCR will reach $118.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $65.00 for Structure Therapeutics in the next year.
View the latest price targets for GPCR.

What is the current consensus analyst rating for Structure Therapeutics?

Structure Therapeutics currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GPCR will outperform the market and that investors should add to their positions of Structure Therapeutics.
View the latest ratings for GPCR.

What other companies compete with Structure Therapeutics?

Other companies that are similar to Structure Therapeutics include Madrigal Pharmaceuticals, Nuvalent, Legend Biotech, Ionis Pharmaceuticals and Blueprint Medicines. Learn More about companies similar to Structure Therapeutics.

How do I contact Structure Therapeutics' investor relations team?

The company's listed phone number is 628-229-9277 and its investor relations email address is [email protected]. The official website for Structure Therapeutics is www.structuretx.com. Learn More about contacing Structure Therapeutics investor relations.